Wyszukaj badanie kliniczne
63 Wyniki
Badanie kliniczne z otwartą rekrutacją
= 
; Badanie kliniczne w toku
= 
; Ufundowane przez członka IRDiRC = 
; MISSING CONTENT = 
Krajowe badania kliniczne
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
Use of telemedicine and artificial intelligence to improve the way patients are referred from community optometrists to hospital eye units
Moorfield's Eye Hospital
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) - AU
Institution: Information not provided - AU
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
EYEGUARD-C: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment (Phase III) - AU
Institution: Information not provided - AU
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation (Phase 1-2) - AT
Institution: Information not provided - AT
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
EYEGUARD-C: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment (Phase III) - CA
Institution: Information not provided - CA
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
VISUAL III: Etude multicentrique en ouvert, évaluant l'efficacité et la tolérance au long cours d'un anti-TNF, l'adalimumab, anticorps monoclonal humain, chez les patients atteints d'uvéite non infectieuse intermédiaire, postérieure ou de panuvéite (phase III).
Institution: Information not provided - FR
PORTUGALIA
CENTRO
ADDRESS: NOT PROVIDED - PT
EYEGUARD-C: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment (Phase III) - PT
Institution: Information not provided - PT
TUNEZJA
TUNISIA
ADDRESS: NOT PROVIDED - TN
EYEGUARD-C: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment (Phase III) - TN
Institution: Information not provided - TN
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis -GB
Institution: Information not provided - US
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FIREFLEYE: Open-label, Randomized, Two-Arm, Controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal (IVT) Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (ROP) (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
FIREFLEYE next: An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090 (Phase 3) - AT
Institution: Information not provided - AT
BELGIA
OOST-VLAANDEREN
GENT
Etude d'extension RAINBOW: une étude d'extension visant à évaluer l'efficacité à long terme et l'innocuité du Ranibizumab par rapport à la thérapie au laser pour le traitement des enfants nés prématurés atteints de rétinopathie du prématuré - BE
Ghent University Hospital - UZ Gent
Department of Ophthalmology
KANADA
Alberta
EDMONTON
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein-1 (REP1) (Phase I)
University of Alberta
CHM
FRANCJA
ILE-DE-FRANCE
PARIS
PNPRO-HC : Essai de prévention de la non-perfusion rétinienne au cours des occlusions de veine centrale rétinienne par traitement à l'hydroxycarbamide (Phase II)
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET
FRANCJA
PAYS DE LA LOIRE
NANTES
IRIS 2: Compensation de la cécité à l'aide du système d'implant rétinien intelligent (IRIS V2) chez des patients atteints de dystrophie rétinienne.
CHU de Nantes - Hôtel Dieu
Service d'ophtalmologie
NIEMCY
Baden-Württemberg
TÜBINGEN
THOR: Klinische Phase II-Studie zur Gentherapie bei Patienten mit Chorioideremie mittels adeno-assoziierter viraler Vektoren (This study is enrolling participants by invitation only)
Department für Augenheilkunde Tübingen
Universitäts-Augenklinik
NIEMCY
Baden-Württemberg
TÜBINGEN
GEMINI-Studie: Eine Open-Label-Studie zur Sicherheit der retinalen Gentherapie bei Chorioideremie mit bilateraler, sequentieller Verabreichung von AAV (Adeno-Associated Viral)-Vektors 2 (AAV2), der das Rab-Escort-Protein 1 (REP1) kodiert -DE-
Department für Augenheilkunde Tübingen
Universitäts-Augenklinik
NIEMCY
Baden-Württemberg
TÜBINGEN
STAR: Eine randomisierte, offene, Outcome-Assessor blinde, prospektive, parallel-Gruppen kontrollierte, klinische Phase 3-Studie zur Retina-Gentherapie bei Chorioideremie mit einem Adeno-assoziierten Virusvektor (AAV2), der das Rab Escort Protein 1 (REP1) kodiert.
Department für Augenheilkunde Tübingen
Universitäts-Augenklinik
NIEMCY
Berlin
BERLIN
ROPROP: Orales Propranolol zur Prävention einer höhergradigen Frühgeborenen-Retinopathie -DE-
Charité - Universitätsmedizin Berlin (CCM)
Klinik für Neonatologie
NIEMCY
Nordrhein-Westfalen
BONN
IRIS 2: Behandlung von Blindheit mit dem intelligenten Netzhautimplantatsystem (IRISV2) bei Patienten mit Netzhautdystrophie
Universitäts-Augenklinik Bonn
HOLANDIA
Zuid-Holland
LEIDEN
SPECTRA studie: Studie naar halve dosis fotodynamische therapie versus eplerenon bij chronische centrale sereuze chorioretinopathie (fase IV)
LUMC - Leids Universitair Medisch Centrum
Afdeling Oogheelkunde
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
FIREFLEYE: Ensayo abierto, aleatorizado, de dos brazos y controlado para evaluar la eficacia, seguridad y tolerabilidad de aflibercept intravítreo (IVT) en comparación con fotocoagulación con láser en pacientes con retinopatía del prematuro (ROP) - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
FIREFLEYE next: Estudio de extensión para evaluar los resultados a largo plazo de los pacientes que recibieron tratamiento para la retinopatía del prematuro en el ensayo 20090 - ES
Institution: Information not provided - ES
SZWECJA
Region Västra Götaland
GÖTEBORG
A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity
The Queen Silvia Children's Hospital - Sahlgrenska
Department of clinical neurosciences
SZWAJCARIA
Suisse Alémanique
ZÜRICH
ROPROP: Oral Propranolol for prevention of thresholdretinopathy of prematurity - CH
Universitätspital Zürich
Klinik für Neonatologie
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Moorfield's Eye Hospital
ZJEDNOCZONE KRÓLESTWO
Oxfordshire
OXFORD
An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Le Gros Clark Building - University of Oxford
Neuroscience
HISZPANIA
Madrid
MADRID
Setmelanotide (RM-493): Ensayo de tratamiento en fase 2 de Setmelanotida (RM-493) en pacientes con trastornos genéticos raros de obesidad
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
HISZPANIA
Madrid
MADRID
Ensayo de fase III de setmelanotida (RM-493), un agonista del receptor de melanocortina-4 (MC4R), en pacientes con síndrome de Bardet-Biedl (SBB) y síndrome de Alström (SA) con obesidad de moderada a grave
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
ZJEDNOCZONE KRÓLESTWO
West Midlands
BIRMINGHAM
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic
BELGIA
OOST-VLAANDEREN
GENT
Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis).
Ghent University Hospital - UZ Gent
Department of Ophthalmology
BELGIA
OOST-VLAANDEREN
GENT
INSIGHT: Een open-label, extensieonderzoek om de veiligheid, verdraagbaarheid, werkzaamheid en farmacokinetiek van QR-110 te evalueren bij personen met Leber congenitale amaurose (LCA) vanwege de c.2991 + 1655A> G-mutatie (p.Cys998X) in het CEP290-gen - BE
Ghent University Hospital - UZ Gent
Department of Ophthalmology
BELGIA
OOST-VLAANDEREN
GENT
ILLUMINATE: Dubbel gemaskeerd, gerandomiseerd, gecontroleerd onderzoek met meerdere doses om de werkzaamheid, veiligheid, verdraagbaarheid en systemisch blootstelling van QR-110 te evalueren in Leber congenitale amaurose (LCA) als gevolg van c.2991 + 1655A> G-mutatie (p.Cys998X) in het CEP290-gen - BE
Ghent University Hospital - UZ Gent
Department of Ophthalmology
BELGIA
OOST-VLAANDEREN
GENT
STELLAR: Een studie om de veiligheid en verdraagbaarheid van QR-421a te evalueren voor de eerste maal bij personen met retinitis pigmentosa (RP) als gevolg van mutaties in Exon 13 van het USH2A-gen -BE
Ghent University Hospital - UZ Gent
Department of Ophthalmology
FRANCJA
GRAND-EST
STRASBOURG
ILLUMINATE: Une étude en double aveugle, randomisée, contrôlée et à doses multiples visant à évaluer l'efficacité, la sécurité, la tolérabilité et les effets systémiques d'une exposition de QR-110 chez des sujets atteints d'amaurose congénitale de Leber (ACL) dûe à la mutation c.2991+1655A›G (p.Cys998X) dans le gène CEP290
CHU de Strasbourg - Hôpital Civil
Centre des Affections Rares en Génétique Ophtalmologique - CARGO
FRANCJA
ILE-DE-FRANCE
PARIS
Etude d'escalade de dose de phase I/IIa évaluant la sécurité de l'injection subrétinienne de SAR422459 chez les patients atteints de la maladie de Stargardt - FR
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET
FRANCJA
ILE-DE-FRANCE
PARIS
ILLUMINATE: Une étude en double aveugle, randomisée, contrôlée et à doses multiples visant à évaluer l'efficacité, la sécurité, la tolérabilité et les effets systémiques d'une exposition de QR-110 chez des sujets atteints d'amaurose congénitale de Leber (ACL) dûe à la mutation c.2991+1655A›G (p.Cys998X) dans le gène CEP290
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET
FRANCJA
ILE-DE-FRANCE
PARIS
STELLAR: étude d'évaluation de l'innocuité et de la tolérabilité de QR-421a chez des sujets présentant une RP dûe aux mutations de l'exon 13 du gène USH2A
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET
FRANCJA
PAYS DE LA LOIRE
NANTES
Etude de sécurité et d'efficacité après administration unilatérale sous-rétinienne de HORA-PDE6B chez des patients atteints de rétinite pigmentaire porteurs de mutations du gène PDE6B conduisant à un défaut d'expression de la protéine PDE6ß (Phase I-II)
CHU de Nantes - Hôtel Dieu
Centre d'investigation clinique (CIC)
NIEMCY
Baden-Württemberg
TÜBINGEN
Sicherheit und Wirksamkeit einer einzelnen subretinalen Injektion von rAAV.hCNGA3 bei Patienten mit Achromatopsie bedingt durch Mutationen in CNGA3, untersucht in einer explorativen Studie mit ansteigender Dosierung (RD-Cure Gentherapie-Studie)
Department für Augenheilkunde Tübingen
Universitäts-Augenklinik
NIEMCY
Baden-Württemberg
TÜBINGEN
ILLUMINATE: Doppelmaskierte, randomisierte, kontrollierte, Multi-Dosis-Studie zur Bewertung von Wirksamkeit, Sicherheit, Verträglichkeit und syst. Exposition von QR-110 bei Amaurosis congenita Leber (LCA) Aufgrund von c.2991+1655A>G-Mutation (p.Cys998X) im CEP290-Gen
Department für Augenheilkunde Tübingen
Universitäts-Augenklinik
WŁOCHY
CAMPANIA
NAPOLI
Studio di sicurezza ed efficacia in soggetti con Amaurosi Congenita di Leber (ACL) tramite vettore adeno-associato per trasferire il gene RPE65 umano nell epitelio pigmentato della retina (EPR): trattamento e follow-up di 3 pazienti italiani
AOU Università degli Studi della Campania "Luigi Vanvitelli"- Cappella Cangiani
U.O.C. di Oculistica
HISZPANIA
Cataluña
BARCELONA
Estudio de fase IIb, aleatorizado, doble ciego y controlado para establecer la seguridad y la eficacia de Zimura (inhibidor del C5 del complemento) en comparación con un tratamiento simulado en pacientes con enfermedad de Stargardt autosómica recesiva
Centro Médico Teknon - Grupo Quirónsalud
Servicio de Oftalmología
HISZPANIA
Madrid
MADRID
Estudio SeaSTAR: Estudio en fase III, multicéntrico, aleatorizado y con doble ciego para comparar la eficacia y la seguridad de clorhidrato de emixustat con placebo para el tratamiento de la atrofia macular secundaria a la enfermedad de Stargardt
Hospital Universitario Fundación Jiménez Díaz
Servicio de Genética Clínica
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
A clinical trial of AAV - CNGA3 retinal gene therapy for patients with achromatopsia -GB
Moorfield's Eye Hospital
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-Associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children with Retinal Dystrophy -GB
Moorfield's Eye Hospital
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
An Open-Label Dose Escalation Study of an Adeno-Associated Virus Vector (AAV2/2-hRPE65p-hRPE65) for Gene Therapy of Severe Early-Onset Retinal Degeneration (Phase I-II)
UCL Institute of Ophthalmology
Molecular Therapy
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/5-hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
University College London - UCL Darwin Building
University College London
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3
University College London - UCL Darwin Building
University College London
STANY ZJEDNOCZONE AMERYKI
Oregon
PORTLAND
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2 - US
OHSU Doernbecher Children's Hospital -Oregon Health & Science University
Casey Eye Institute
Wieloośrodkowe badania kliniczne
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
EYEGUARD-A: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis (Phase III) (TERMINATED)
Moorfield's Eye Hospital
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis
Institution: Information not provided - US
NIEMCY
Berlin
BERLIN
ROPROP: Orales Propranolol zur Prävention einer höhergradigen Frühgeborenen-Retinopathie
Charité - Universitätsmedizin Berlin (CCM)
Klinik für Neonatologie
SZWAJCARIA
Suisse Alémanique
BASEL
RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Novartis International AG
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Institution: Information not provided - US
HOLANDIA
Zuid-Holland
LEIDEN
HOLANDIA
Zuid-Holland
LEIDEN